In France, Enterome SA, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announced the joint creation of Microbiome Diagnostics Partners. MDP will bring together complementary, world-leading platforms and capabilities enabling the discovery, development and commercialization of innovative diagnostics in multiple diseases areas, including inflammatory bowel diseases and liver diseases.
MDP will be a 50/50 joint venture between Enterome and Nestlé Health Science. Enterome will contribute its current microbiome diagnostic programs and intellectual property derived from its unique microbiome-based platform for the development of diagnostics in all therapeutic areas except immuno-oncology. Prometheus Laboratories (a Nestlé Health Science Company) will contribute its diagnostics development and commercialization expertise.
Nestlé Health Science will invest €20 million in return for its 50 percent stake and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive milestone payments linked to the success of clinical and commercial activities.